Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Director | March 15, 2024 | March 19, 2024 |
| NEUROPATHIX, INC.NPTX · Entity 126275 | Director | March 12, 2021 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date March 15, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2034-03-01 | Direct | 4,500,000 |
Reported balance
After 2024-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 35,000 · Balance 4,500,000 F1: Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.
NEUROPATHIX, INC.
Report date March 12, 2021 · Filed March 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2031-03-11 | Direct | 600,000 |
Reported balance
After 2021-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-12 · Grant · Acquired 600,000 · Balance 600,000 F1: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 19:37 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 35,000 | $35,000.00 Strike: $0.01 | $1,225,000,000.00 |
DisclosureSEC source: 0001096906-24-000522 · form4.xml · derivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500,000 Underlying: Common Stock · 3,500,000 shares Expires 2034-03-01 F1 · shares: Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 18:06 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 1,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001096906-22-002340 · form4.xml · derivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-08-22 F1 · derivative.exercise_date: Reporting Person acquired an option to purchase up to 1,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date. Read SEC document |
| August 22, 2022 Filed Aug 26, 2022 17:05 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | ConversionCommon Stock | 854,012 | $0.03 | $24,766.35 |
DisclosureSEC source: 0001096906-22-002027 · form4.xml · nonDerivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Conversion of Note Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 18:04 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | OtherConvertible Note (Convertible into Common Stock) · Derivative | 25,000 | $25,000.00 Strike: $0.08 | $625,000,000.00 |
DisclosureSEC source: 0001096906-22-000339 · form4.xml · derivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,692 Underlying: Common Stock · 307,692 shares Expires 2032-02-10 F1 · kind: This Note bears interest at a rate of 3% per annum. At the election of the Reporting Person, all principal and accrued interest under the Note may be converted into the Issuer's common stock at a converstion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Issuer's common stock in the ten (10) days prior to the date of conversion. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:56 UTC | NEUROPATHIX, INC. NPTX · Entity 126275 | GrantEmployee Stock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001607062-21-000052 · primary_doc.xml · derivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months thereafter. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:47 UTC | NEUROPATHIX, INC. KLFE · Entity 126275 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001683168-20-001432 · ownership.xml · derivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-05-03 F1 · derivative.exercise_date: 1/4th of the option shares vest on the date of grant and the remaining option shares vest in equal monthly installments over 36 months commencing with the vesting commencement date of January 1, 2020. Read SEC document |
| August 14, 2019 Filed May 6, 2020 21:39 UTC | NEUROPATHIX, INC. KLFE · Entity 126275 | GrantCommon Stock | 250,000 | $0.10 | $25,000.00 |
DisclosureSEC source: 0001683168-20-001425 · ownership.xml · nonDerivative · entry 1 Schroeder Blake · CIK 0001708685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.